BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

HiRO Acquires DeltaMed Solutions, Expands Across 10 Countries

Harvest Integrated Research Organization (HiRO), a full-service, boutique global CRO, is excited to announce its latest strategic move with the successful ...

July 02, 2024 | News

IASO Biotechnology Secures NMPA Approval for IND Application of RD118 CAR-T Therapy Targeting GPRC5D for Relapsed/Refractory Multiple Myeloma

IASO Biotechnology , a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies and antibody pr...

July 01, 2024 | News

Simcere Zaiming's Enlituo® Receives NMPA Approval for mCRC Treatment

Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetu...

June 27, 2024 | News

Porton Advanced Integrates MaxCyte cGMP-Grade Electroporation System into Cell Therapy Platform

Porton Advanced recently introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as ...

June 26, 2024 | News

FDA Approves iRegene's NouvNeu001, Marking Milestone in Parkinson's Disease Treatment

U.S. Food and Drug Administration (FDA) approved the IND application for NouvNeu001, a cell therapy product from iRegene therapeutics targeting Parkinson's...

June 25, 2024 | News

EU Approves HUTCHMED's FRUZAQLA® for Previously Treated Metastatic Colorectal Cancer

— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZ...

June 24, 2024 | News

Dizal's Golidocitinib Approved in China as First JAK1-Only Inhibitor for Relapsed or Refractory Peripheral T-Cell Lymphoma

Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational piv...

June 20, 2024 | News

YolTech Partners with KACTUS to Commercialize Breakthrough DNA Editor YolCas12TM in Greater China

YolTech, a clinical-stage biopharmaceutical company specializing in mRNA-LNP delivery for in vivo gene editing therapies, has partnered with KACT...

June 19, 2024 | News

ReviR Therapeutics and Asieris Pharmaceuticals Achieve Milestone in Cancer Treatment Collaboration

ReviR Therapeutics, a biotechnology company specializing in the development of small molecule RNA splicing modulators for neurogenetic diseases and oncolog...

June 18, 2024 | News

FDA Clears Zymeworks' ZW171 for Mesothelin-Expressing Cancers

“We are excited to reach this R&D milestone with ZW171, reflecting our commitment to advancing innovative therapies for cancer treatment,...

June 18, 2024 | News

Venus Medtech Achieves Milestone with First U.S. Implantation of VenusP-Valve in PROTEUS Study

Venus Medtech, a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced today th...

June 17, 2024 | News

Ascentage Pharma Secures $1.3 Billion Deal with Takeda for Global Rights to Olverembatinib

Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas. ...

June 17, 2024 | News

Ethypharm Expands Portfolio with Acquisition of Mesalazine Suppository by Chinese Affiliate

Ethypharm is pleased to announce the acquisition of a suppository form of Mesalazine by its Chinese affiliate, Shanghai Ethypharm Pharmaceuticals Ltd, from...

June 14, 2024 | News

Zymeworks Secures $8 Million Milestone Payment and Advances Cancer Treatment with FDA and NMPA Approvals

Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from Bei...

June 11, 2024 | News

Stay Connected